In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.
Request InsightsPurchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively. Request Insights
IN THE NEWSOrion Pharma AB to acquire the clearance for darolutamide indication in the combination with docetaxel from U.S. Food and Drug Administration (FDA). The product is developed for the treatment of metastatic hormone-sensitive prostate cancer shortly known as (mHSPC).
Genentech, Inc. to release positive results from the Phase III SKYSCRAPER-01 study. The study was being conducted to monitor the anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) vs Tecentriq alone as an initial (first-line) to find the cure for people living with advanced or metastatic non-small cell lung cancer (NSCLC).
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~8% |
|
Base Year Market Size (2022) |
~ USD 32 Billion |
|
Forecast Year Market Size (2033) |
~ USD 57 Billion |
|
Regional Scope |
|
The global hormone replacement therapy market is estimated to garner a revenue of ~USD 57 billion by the end of 2033 by growing at a CAGR of ~8% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 32 billion in the year 2022. The growth of the market is primarily attributed to the higher prevalence of chronic conditions such as hypogonadism in adult males across the globe. For instance, globally, hypogonadal males account for approximately 42% of men over the age of 45 and 55% of men in their 80s. Moreover, rising awareness regarding the post- menopausal issues among women is another major factor which is driving the growth of the market over the projected forecast period.
Get more information on this report:Request Sample PDF
Global hormone replacement therapy market trends such as, skyrocketing investment by the government in the R&D of new medical technology and the growing prevalence of high blood pressure & hypertension are projected to influence the growth of the market positively over the forecast period. For instance, it is estimated that in every 4 adults, 1 of them aged between 20 to 45 suffers from high blood pressure worldwide. Additionally, in 2018, around 45% of the global population was projected to live with hypertension. Hence, all these factors are anticipated to propel the growth of the market over the forecast period.
Higher Number of Women Hitting Menopause - As of 2020, in the USA, around 50% of women aged 35 or above were facing sleep problems, 45% of them had skin dryness, 30% suffering from depression, and 30% women were living with night sweats due to menopause. Menopause is a time that comes in a women’s life after she has her last menstrual cycle. Menopause is commonly diagnosed after 12 months without having a menstrual period which generally occurs in the 40s or 50s. During this period, women face severe hormonal changes that can affect their daily life. Hence, hormone replacement therapy becomes beneficial to soothe the symptoms of menopause.
Growing Cases of Anxiety Disorders - In 2019, around 4% of the global population was estimated to be suffering from anxiety disorders.
Spiking Prevalence of Thyroid in Modern Population - For instance, approximately 10 out of 100,000 women and 3 out of 100,000 men are projected to be living with thyroid.
Worldwide Proliferation in Hypertension - For instance, approximately 1.50 billion people globally between the ages of 30-79 had hypertension in 2021.
Utilization of Hormone Replacement Therapy to Cure Liver Disease - It has been observed that around 1.8 million people die due to liver disease every year across the globe.
Possibilities of Side-Effects of the Therapy – Hormone replacement therapy is anticipated to cause some problems with digestive system of that person who takes this therapy. A person feels sick, have diarrhea, constipation, and even loss of appetite.
Requirement for Higher Initial Investment
Lack of Skilled Medical Professionals
The global hormone replacement therapy market is segmented and analyzed for demand and supply by administration route into parenteral, transdermal, and oral, out of which, the transdermal segment is projected to witness noteworthy growth over the forecast period. The growth of the segment is accounted to the rising demand for transdermal drug delivery and ease of application. For instance, it is estimated that over 1 million transdermal patches are produced worldwide every year.
The North America hormone replacement therapy market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The growth of the market is ascribed to the significant growth in the geriatric population along with the significant presence of a well-structured healthcare infrastructure. World Bank released a set of data showing the geriatric population in the United States reached 56,545,938 in 2021. Moreover, rising cases of cancer and spiking penetration of major key players of the market in the region are further expected to hike the growth of the market over the forecast period.
Our in-depth analysis of the global hormone replacement therapy market includes the following segments:
|
By Replacement Therapy |
|
|
By Administration Route |
|
|
By Indication |
|
FREQUENTLY ASKED QUESTIONS
Higher number of women hitting menopause and growing cases of anxiety disorders is estimated to majorly boost the market growth.
The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2033.
Possibilities of side-effects of the therapy and the requirement for higher initial investment are estimated to challenge the market growth.
The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
The major players in the market are Abbott Laboratories, Novo Nordisk A/S, Genentech, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Merck KGaA, Mylan N.V., Bayer AG, Eli Lilly and Company, and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.
The market is segmented by replacement therapy, administration route, indication, and by region.
The transdermal is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions | LOB
Copyright © 2022 Research Nester. All Rights Reserved
